Clinical profiles in multiple myeloma patients with extreme survivals: a study from a National Medical Center in China.
Multiple myeloma
chemotherapy
extreme survivals
prognostic biomarker
Journal
Hematology (Amsterdam, Netherlands)
ISSN: 1607-8454
Titre abrégé: Hematology
Pays: England
ID NLM: 9708388
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
30
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
The clinical outcomes of multiple myeloma (MM) patients are highly variable in the real-world setting. Some MM patients may have clinical endings that do not abide by the book. We aim to describe features of MM patients with extreme survivals in real-world practice. This retrospective study enrolled 941 patients consecutively visited a national medical center, China, between July 1995 and December 2021. Among patients, we identified two groups of MM patients with extreme survivals, 56 were in the long-term remission (LR) group with progression-free survival (PFS) ≥ 60 months, and 82 were in the rapid progression (RP) group with PFS ≤ 6 months. CRAB features, of which hypercalcemia, renal insufficiency, and anemia were more common in the RP group, except for bone disease, with a comparable incidence at diagnosis in both groups (88.8 vs 85.7%, The disparities in the survivals of MM patients indicated that some unexpected factors have influenced the outcomes in the real-world setting.
Identifiants
pubmed: 38018564
doi: 10.1080/16078454.2023.2277503
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM